JPRN-jRCTs031180365已完成未知
Efficacy and safety of transcatheter arterial chemoembolization with warmed miriplatin for unresectable hepatocellular carcinoma - Miriplatin TACE study
Watadani Takeyuki0 个研究点目标入组 3 人开始时间: 2019年3月18日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 3
研究概览
简要总结
Arterial embolization with heated Miriplatin for non-resectable hepatocellular carcinoma was performed in 3 patients, and no severe adverse events occurred.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 85age old（—）
- 性别
- All
入选标准
- •1.Hepatocellular carcinoma not appropriate for surgery or local ablation therapy (e.g. radiofrecuency ablation)
- •2.Hypervascular hepatocellular carcinoma proven by imaging test (CT, MRI, US) regardless of the presence or absence of history of TACE
- •3.Age greater than or equal to 20, <85
- •4.Written informed consent
排除标准
- •1.Liver dysfunction (Child-Pugh C)
- •2.Total bilirubin greater than or equal to 3mg/dL
- •3.eGFR < 30mL/min/1.73m2
- •4.History of allergy or severe complication of TACE
- •5.History of severe allergy of platinum-containing drugs including miriplatin or iodine agents
- •6.Severe thyroid disease
- •7.Pregnant, unwilling to practice contraception during the study, or lactating female
- •8.Dementia
- •9.Inappropriate patients for this study judged by the physicians.
研究者
相似试验
已完成
不适用
Transarterial Chemoembolization Plus Hypofractionnated Radiotherapy vs. Surgery in Locally Advanced Hepatocellular Carcinoma: an IPTW ComparisonNon-metastatic Hepatocellular CarcinomaNCT04823715Hospices Civils de Lyon163
招募中
不适用
TACE-HAIC vs. HAIC for Potentially Resectable HCCPotentially ResectionHepatocellular CarcinomaNCT03591705Sun Yat-sen University240
已完成
2 期
Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +AxitinibHepatocellular CarcinomaNCT01352728Chinese University of Hong Kong50
终止
2 期
Transarterial Chemoembolization Versus Stereotactic Body Radiation Therapy for Hepatocellular CarcinomaLiver NeoplasmsNCT02470533Erasmus Medical Center100
招募中
2 期
Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical TrialHepatocellular CarcinomaNCT05751343Sun Yat-sen University55